Gapping up
In reaction to disappointing earnings/guidance:
- NFLX +7%, CE +6.2%, WTFC +2.4%, MLNX +2.1%, UNH +2%, JNJ +0.9%, IHG +0.7%, GS +0.6%
Other news:
- ROKU +8.4% (ESPN+ direct-to-consumer subscription streaming service now available on Roku devices; Point72 Asset Management disclosed 5.1% passive stake)
- ARQL +7.4% (enters into license agreement with Basilea Pharmaceutica; Basilea will make an upfront payment to ArQule of $10 mln)
- IDRA +6.8% (presents data from a study evaluating a combination regimen that involved the TLR-9 agonist tilsotolimod and checkpoint inhibitors targeting two negative immune regulators, IDO-1 and PD-1 to eliminate established tumors in syngeneic tumor models)
- PUMP +6.3% (to join S&P SmallCap 600)
- JILL +2.9% (Director disclosed purchase of 100000 shares valued at approx $499.8K)
- CLVS +2% (prices upsized underwritten public offering of $300 mln aggregate principal amount of its 1.25% convertible senior notes due 2025; additionally prices 1,837,898 shares of its common stock at $54.41 per share)
- LULU +1.7% (appoints Patrick Guido as Chief Financial Officer, effective April 30, 2018)
- CRSP +1.6% (presents 'positive' data on allogeneic CRISPR-based CAR-T cell therapies at AACR 2018 )
- MTSI +1.4% (M/A-COM Tech comments on recent U.S. Department of Commerce export ban)
- HMNY +1% (continued strength)
- MNK +1% (repays $300 mln of unsecured, fixed-rate notes maturing April 15, 2018 with cash on hand), .
Analyst comments:
- IIN +4.6% (initiated with a Buy at Stifel)
- VIVE +4.2% (initiated with a Buy at Stifel)
- DBX +2.7% (initiated with a Overweight at JP Morgan)
- DG +2% (upgraded to Overweight from Neutral at JP Morgan)
- CCE +1.5% (upgraded to Buy from Neutral at Goldman)
- ABB +0.7% (upgraded to Neutral from Sell at UBS)
![]()